Streetbeat News

ATHX

Athersys Inc

http://www.athersys.com/

CEO

Gil Van Bokkelen

Employees

Industry

Pharmaceutical Preparation Manufacturing

athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. we are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. this pipeline includes both stem cell therapy and pharmaceuticals.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

0.10

P/E Ratio

-0.06

52-wk high

0.10

Low

0.10

Div yield

N/A

52-wk low

0.10

U.S. stocks traded higher with the Dow Jones gaining around 175 points. Neogen Corporation reported weaker-than-expected results for its first quarter. SMX shares shot up 62% after the company announced it secured a majority stake in True Gold Consortium. Shares of Intrusion Inc. and Startek, Inc. also rose significantly. Akero Therapeutics, Athersys, Inc., and Ventyx Biosciences saw their shares drop after reporting disappointing results or news.

Portfolio Pulse from Lisa Levin

October 10, 2023 | 6:46 pm

During Tuesday's intraday session, several healthcare stocks experienced significant movements. Gainers included Inovio Pharmaceuticals (INO), NanoString Technologies (NSTG), Scinai Immunotherapeutics (SCNI), Cyclerion Therapeutics (CYCN), Carmell Therapeutics (CTCX), and Vicarious Surgical (RBOT). Losers included Akero Therapeutics (AKRO), Athersys (ATHX), 89bio (ETNB), Ventyx Biosciences (VTYX), Protagenic Therapeutics (PTIX), and Nuwellis (NUWE).

Portfolio Pulse from Benzinga Insights

October 10, 2023 | 5:31 pm

Several stocks experienced significant movement in Tuesday's mid-day session. Notable gainers include SuperCom Ltd., SMX (Security Matters) Public Limited Company, PowerFleet, Inc., SaverOne 2014 Ltd, Intrusion Inc., Startek, Inc., CISO Global Inc., Mobilicom Limited, PGT Innovations, Inc., NanoString Technologies, Inc., Erasca, Inc., Processa Pharmaceuticals, Inc., MDxHealth SA, Lexicon Pharmaceuticals, Inc., ContraFect Corporation, Canopy Growth Corporation, Coherent Corp., Opendoor Technologies Inc., Rackspace Technology, Inc., Hyatt Hotels Corporation, and Immunic, Inc. Notable losers include Akero Therapeutics, Inc., Athersys, Inc., 89bio, Inc., HUB Cyber Security Ltd., Gamer Pakistan Inc., ParaZero Technologies Ltd., Ventyx Biosciences, Inc., Molekule Group, Inc., Maris-Tech Ltd., Maison Solutions Inc., Fitell Corporation, Nxu, Inc., Phoenix Motor Inc., Safe and Green Development Corporation, John Wiley & Sons, Inc., Falcon's Beyond Global, Inc., Lipella Pharmaceuticals Inc., RVL Pharmaceuticals plc, Groupon, Inc., Borqs Technologies, Inc., VIA optronics AG, and PagerDuty, Inc.

Portfolio Pulse from Lisa Levin

October 10, 2023 | 5:08 pm

Athersys announced its intention to conduct additional data analysis with independent statisticians due to the insufficient sample size in the Phase 3 MASTERS-2. This has led to a decrease in the company's share price.

Portfolio Pulse from Bill Haddad

October 10, 2023 | 3:55 pm

US stocks traded higher with the Dow Jones gaining more than 50 points. PepsiCo Inc reported better-than-expected earnings for its third quarter, with sales growth of 6.7% year-on-year to $23.45 billion. SMX, SuperCom Ltd, and CISO Global Inc shares rose significantly, while Akero Therapeutics, Athersys, Inc, and 89bio, Inc shares dropped. Oil traded down 0.4% while gold traded up 0.2%.

Portfolio Pulse from Lisa Levin

October 10, 2023 | 1:40 pm

Several healthcare stocks experienced significant movement in Tuesday's pre-market session. Immunic, MDxHealth, Synlogic, Inovio Pharmaceuticals, Moleculin Biotech, and NanoVibronix saw gains, while Akero Therapeutics, Athersys, 89bio, iSpecimen, Ventyx Biosciences, and RVL Pharmaceuticals experienced losses.

Portfolio Pulse from Benzinga Insights

October 10, 2023 | 1:06 pm

Trading of Athersys, Inc. shares is set to resume at 9:00 a.m. ET.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:51 pm

Athersys, Inc. (NASDAQ:ATHX) has reported interim analysis results of its MASTERS-2 clinical study with MultiStem in ischemic stroke, indicating that the current sample size of 300 patients is insufficient to achieve the primary endpoint. The company plans to conduct additional data analysis and pause enrollment of new patients. Athersys has also signed a Memorandum of Understanding (MOU) with HEALIOS K.K. for global ARDS license, which includes $1.5M to $4.5M near term payments and up to $150M in milestones. If Athersys is unable to secure a strategic transaction or adequate financing, it may have to file for bankruptcy protection.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:38 pm

Trading of Athersys shares has been temporarily halted due to pending news.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:25 pm

Athersys has licensed its animal health assets to Ardent Animal Health. The agreement includes an initial fee, pre and post-regulatory milestone payments, and royalties on commercial sales.

Portfolio Pulse from Bill Haddad

October 03, 2023 | 8:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.